Active Biotech AB

ACTI

SE0001137985

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm Other stock markets 09:30:00 28/06/2024 pm IST			5-day change	1st Jan Change
0.4895 ^SEK	-2.10%		-1.71%	+7.23%

22/05	Active Biotech Secures Exclusive Licensing Rights to Multiple Myeloma Drug	MT
22/05	Active Biotech Enters into an Exclusive License Agreement with the Wistar Institute of Anatomy and Biology	CI

Active Biotech AB Appoints Elaine Sullivan as A Director

November 25, 2020 at 12:30 pm IST

IP Group plc announced that Elaine Sullivan, a non-executive director of the Group, has been appointed as a director of the Active Biotech AB.

Latest news about Active Biotech AB

Active Biotech Secures Exclusive Licensing Rights to Multiple Myeloma Drug	22/05	MT
Active Biotech Enters into an Exclusive License Agreement with the Wistar Institute of Anatomy and Biology	22/05	CI
Active Biotech AB Reports Earnings Results for the First Quarter Ended March 31, 2024	08/05	CI
Active Biotech AB Announces Start of Enrollment to the Clinical Phase I Biodistribution Study with Laquinimod Eye Drops	03/04	CI
Active Biotech AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	08/02	CI
Active Biotech AB Reports Earnings Results for the Full Year Ended December 31, 2023	08/02	CI
Active Biotech AB Provides Update on the Scheduled Clinical Program for 2024	22/12	CI
Active Biotech Raises SEK44 Million via Rights Offering	06/12	MT
Active Biotech Teams Up with US Research Group on Clinical Study of Laquinimod Eye Drops	06/12	MT
Active Biotech AB Appoints Mats Arnhög and Petter Wingstrand to Nomination Committee	01/12	CI
Active Biotech Plans SEK51 Million Rights Issue; Shares Sink	09/11	MT
Active Biotech AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11	CI
Active Biotech AB Announces Two Abstracts with Preclinical Data for Tasquinimod in Myelofibrosis and Myelodysplastic Syndrome Have Been Accepted for Presentation At Ash 2023	02/11	CI
Active Biotech AB Announces Successful Completion of Dose Escalation of Tasquinimod	11/23/11	CI
Active Biotech AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	24/23/24	CI
Active Biotech Signs Collaboration Deal For Blood Cancer Drug Clinical Trial	31/23/31	MT
Active Biotech AB Enters into Clinical Trial Collaboration Agreement for a Clinical Study with Tasquinimod in Myelofibrosis	31/23/31	CI
Active Biotech Announces Positive Interim Data from an Ongoing Study with Tasquinimod in Relapsed and Refractory Multiple Myeloma	26/23/26	CI
Active Biotech AB Reports Earnings Results for the First Quarter Ended March 31, 2023	04/23/04	CI
Active Biotech AB Auditor Raises 'Going Concern' Doubt	26/23/26	CI
Active Biotech AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	09/23/09	CI
Active Biotech AB Reports Earnings Results for the Full Year Ended December 31, 2022	09/23/09	CI
Active Biotech AB Confirms Positive Clinical Safety Profile of Laquinimod Eye Drops	30/23/30	CI
Active Biotech's Announces Nomination Committee	05/22/05	CI
Active Biotech AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	03/22/03	CI

Active Biotech AB (publ) is a Sweden-based Company, which develops pharmaceutical products within medical areas where the immune defense is important, including cancer and inflammatory diseases. The project portfolio comprises both small, orally active immunomodulatory molecules and antibody-based immunotherapy.

Sector

Biotechnology & Medical Research

Calendar

22/08/2024 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Chiffre d''affaires - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ACTIVE BIOTECH AB	+7.23%	1.67Cr
VERTEX PHARMACEUTICALS INCORPORATED	+15.20%	12TCr
REGENERON PHARMACEUTICALS, INC.	+19.67%	11TCr
ARGENX SE	+18.95%	2.6TCr
BIONTECH SE	-23.86%	1.94TCr
GENMAB A/S	-19.03%	1.59TCr
BEIGENE, LTD.	-20.90%	1.51TCr
WUXI APPTEC CO., LTD.	-46.14%	1.51TCr
SAREPTA THERAPEUTICS, INC.	+63.85%	1.49TCr
NEUROCRINE BIOSCIENCES, INC.	+4.49%	1.39TCr

Bio Therapeutic Drugs